Viatris Inc vs Western Alliance Bancorporation — how do they compare? Viatris Inc trades at $17.58 (market cap $19.79B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: Viatris Inc is far larger — about 2.2× Western Alliance Bancorporation's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| VTRS | WAL | |
|---|---|---|
Market Cap | $19.79B | $8.84B |
Sector | Health | Financials |
52-Week High | $17.39 | $96.08 |
52-Week Low | $8.74 | $66.70 |
Enterprise Value | $32.00B | — |
Dividend Yield | 2.83% | 2.07% |
Trailing returns across standard periods
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →